MedTrace Logo

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

NCT04157140 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-12-03

No results posted yet for this study

Summary

A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial chemoembolization(TACE) in patients with middle-advanced hepatocellular carcinoma(HCC)

Conditions

Interventions

DRUG

Anlotinib

12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.

DEVICE

TACE+RFA

TACE first, followed by RFA within day7（+/-3days）

Sponsors & Collaborators

  • Jinglong Chen

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-28
Primary Completion
2022-09-01
Completion
2023-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04157140 on ClinicalTrials.gov